Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity

TLDR

Anticancer vaccines train the immune system to recognize malignant cells based on antigen expression, yet clinical efficacy is limited by the similarity between cancer and healthy tissue. The study aims to create a vaccine that delivers multiple tumor antigens to potently stimulate endogenous immune responses. A biomimetic nanoparticle vaccine was fabricated to co‑deliver autologous tumor antigens and a strong adjuvant, presenting both simultaneously to maximize antigen presentation and immune activation. The vaccine induced robust antitumor immunity in vivo, and when combined with checkpoint inhibitors, produced substantial therapeutic effects, offering a blueprint for personalized autologous vaccines.

Abstract

Anticancer vaccines train the body's own immune system to recognize and eliminate malignant cells based on differential antigen expression. While conceptually attractive, clinical efficacy is lacking given several key challenges stemming from the similarities between cancerous and healthy tissue. Ideally, an effective vaccine formulation would deliver multiple tumor antigens in a fashion that potently stimulates endogenous immune responses against those antigens. Here, it is reported on the fabrication of a biomimetic, nanoparticulate anticancer vaccine that is capable of delivering autologously derived tumor antigen material together with a highly immunostimulatory adjuvant. The two major components, tumor antigens and adjuvant, are presented concurrently in a fashion that maximizes their ability to promote effective antigen presentation and activation of downstream immune processes. Ultimately, it is demonstrated that the formulation can elicit potent antitumor immune responses in vivo. When combined with additional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates substantial therapeutic effect. Overall, the work represents the rational application of nanotechnology for immunoengineering and can provide a blueprint for the future development of personalized, autologous anticancer vaccines with broad applicability.